Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Proxygen partnered with Germany-based Merck to jointly identify and develop molecular glue degraders for clinical research.
BioSpace spoke with Payton Nyquvest, co-founder and CEO of Numinus about changing perceptions around psychedelic-assisted psychotherapy and the company’s work in this space.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Tessera Therapeutics announced Thursday that ex-AbbVie executive Michael Severino, M.D. will take the helm of the young biotech.
With June just getting started, BMS and Sorrento are making new connections. Read on for announcements of these collaborations.
In partnership with the U.S. government, Evonik Industries is investing more than $200 million to build a lipid manufacturing facility in the United States.
Repare Therapeutics announced a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.
Upstream Bio is focusing its efforts on an experimental treatment for severe asthma licensed from Astellas Pharma.
Seattle-based Sana Biotechnology is moving on from its current Fremont, California manufacturing facility, inking a lease deal to develop a manufacturing plant in Bothell, Washington.
AstraZeneca CEO Pascal Soriot has been knighted in the Queen’s Birthday Honours for his contribution to life sciences and leadership during the COVID-19 pandemic.